Clinical Trials on Human Papillomavirus Vaccine

Total 9106 results

National Liver Institute, Egypt

Unknown

Safety and Efficacy Study of CENV3 Vaccine to Protect Against HCV Infection (CENV3)

Vaccine Overdose of Undetermined Intent

Egypt
Pamela Hull
National Cancer Institute (NCI)

Completed

Increasing HPV Vaccination in Community-Based Pediatric Practices

HPV Vaccines

United States
Pfizer

Completed

A Study to Assess the Safety and Tolerability of Different Doses of PF-05402536 and PF-06413367 in Healthy Adult Smokers.

Smoking | Vaccines

Canada
Pfizer

Completed

13vPnC Multidose Vial Safety, Tolerability and Immunogenicity Study in Healthy Infants.

Pneumococcal Vaccines

Gambia
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Infants

Vaccines, Pneumococcal

Italy
Pfizer

Completed

Study Comparing 13-valent Pneumococcal Conjugate Vaccine With 7-valent Pneumococcal Conjugate Vaccine

Vaccines, Pneumococcal

United States
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants

Vaccines, Pneumococcal

United Kingdom
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating 13-valent Pneumococcal Conjugate Vaccine In Healthy Infants

Vaccines, Pneumococcal

United States
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants.

Vaccines, Pneumococcal

Spain
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants

Vaccines, Pneumococcal

France
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants

Vaccines, Pneumococcal

Poland
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Wyeth Study To Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants

Pneumococcal Vaccines

Poland
University of Washington
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

HPV Infections in Older Women

Papillomavirus Infections

United States
Bandim Health Project
Radboud University Medical Center

Enrolling by invitation

The Non-Specific Immunological Effects of Providing Oral Polio Vaccine to Seniors in Guinea-Bissau

Vaccine Reaction

Guinea-Bissau
Maria de Lourdes de Sousa Maia, MD

Not yet recruiting

Evaluation of the Non-Inferiority of a 12-Valent Pneumococcal Conjugate Vaccine in Healthy Children in Brazil.

Pneumococcal Vaccines
Vaxcyte, Inc.

Completed

Safety, Tolerability, and Immunogenicity Study of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Adults

Pneumococcal Vaccines

United States
Vaxcyte, Inc.

Active, not recruiting

Safety, Tolerability, and Immunogenicity Study of a 31-Valent Pneumococcal Conjugate Vaccine (VAX-31) in Adults

Pneumococcal Vaccines

United States
Inventprise Inc.
PATH; Canadian Center for Vaccinology; Vaccine Evaluation Center, Canada

Active, not recruiting

Dose-Ranging Study to Evaluate a 25-Valent Pneumococcal Conjugate Vaccine

Pneumococcal Vaccines

Canada
Inventprise Inc.
PATH; Canadian Center for Vaccinology; Vaccine Evaluation Center, Canada

Completed

Study to Evaluate a 25-Valent Pneumococcal Conjugate Vaccine (IVT PCV-25)

Pneumococcal Vaccines

Canada
Murdoch Childrens Research Institute
National Health and Medical Research Council, Australia; GlaxoSmithKline; Bill... and other collaborators

Completed

Trial of Pneumococcal Vaccine Schedules in Ho Chi Minh City, Vietnam

Pneumococcal Vaccines

Vietnam
Taipei Medical University Shuang Ho Hospital

Unknown

Using "Decision Aids" to Help the Infant Family to Decide the Use of Oral Rotavirus Vaccine

Rotavirus Vaccines

Taiwan
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants in Mexico

Vaccines, Pneumococcal

Mexico
Pfizer

Completed

Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Children

Pneumococcal Vaccines

Sweden
GlaxoSmithKline

Completed

Monovalent H5N1 Vaccine GSK1557484A in Children 6 Months to < 18 Years of Age

Influenza | Influenza Vaccines

United States, Thailand, Canada
VA Sierra Nevada Health Care System
Merck Sharp & Dohme LLC

Not yet recruiting

Evaluation of PCV15 Vaccination Among PPSV23-experienced, Immunocompromised Elderly Veterans

Immunosuppression | Pneumococcal Vaccines
Pharmacy Quality Alliance

Completed

Immunization Services Model for Adult Rate Improvement (ImmuSMART)

Pharmacy | Immunization | Vaccines
Shanxi Medical University
Centers for Disease Control and Prevention, China

Completed

Immunogenicity of Hepatitis B Vaccination in Methadone Maintenance Treatment Patients

Hepatitis B Vaccine
GlaxoSmithKline

Completed

Long-term Persistence of Immunity to Hepatitis B in Adults Vaccinated With GlaxoSmithKline (GSK) Biologicals' Hepatitis B Vaccine (HBV), Engerix-B

Hepatitis B Vaccine

Belgium, Canada
Vanderbilt University Medical Center
Human Vaccines Project

Completed

Kinetics of the Immune Response to Inactivated Influenza Vaccine in Healthy Adults (KIRV)

Vaccine Reaction | Influenza | Influenza, Human | Influenza A | Influenza Type B | Influenza A H3N2 | Influenza A H1N1

United States
Eisenhower Army Medical Center

Unknown

Gardasil Vaccination as Therapy in Low Grade Cervical Abnormalities

Papillomavirus Infections

United States
Merck Sharp & Dohme LLC

Completed

A Study of the Safety, Tolerability, and Immunogenicity of a 9-valent Human Papillomavirus Vaccine ([9vHPV]; V503) Administered to 9- to 15-Year-Old Japanese Girls (V503-008).

Papillomavirus Infections
GlaxoSmithKline

Completed

Safety and Tolerability Study of GlaxoSmithKline (GSK)1557484A Vaccine in Adults at Occupational Risk for Influenza A (H5N1) Exposure

Influenza | Influenza Vaccines

United States
VBI Vaccines Inc.

Recruiting

PREHEVBRIO Pregnancy Outcomes Registry

Vaccine Exposure During Pregnancy

United States
GlaxoSmithKline

Completed

Safety Evaluation of the GSK-580299 Vaccine in Women From the Control Group in the Primary NCT00294047 Study

Infections, Papillomavirus

United States, Canada
GlaxoSmithKline

Completed

Study to Assess Immune Responses and Safety of the GSK-580299 Vaccine in Healthy Women (26 to 45 Years)

Infections, Papillomavirus

China
GlaxoSmithKline

Completed

Follow-up Study to Evaluate the Long-term Efficacy of the HPV Vaccine (580299) in Healthy Young Adult Women in Brazil

Infections, Papillomavirus

Brazil
GlaxoSmithKline

Completed

Safety and Immunogenicity Study of MEDI-517 (GSK 580299) With or Without Adjuvant in Healthy Adult Females

Infections, Papillomavirus
GlaxoSmithKline

Withdrawn

Antibody Persistence for GlaxoSmithKline (GSK) Biologicals' HPV-16/18 L1 VLP AS04 Vaccine (GSK-580299) Administered in Healthy Adults and Adolescents, 6.5 Years After First Vaccination in the Primary Study

Infections, Papillomavirus
University of Washington
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

High-Risk HPV Infections in Women Aged 25 to 65

Papillomavirus Infections

United States
Xiamen Innovax Biotech Co., Ltd
Zhejiang Provincial Center for Disease Control and Prevention

Active, not recruiting

Immunogenicity and Safety of Co-immunization With Cecolin and Hecolin

Human Papilloma Virus Infection Type 16 | Human Papilloma Virus Infection Type 18 | Hepatitis E Virus Infection

China
GlaxoSmithKline

Completed

Safety and Immunogenicity of GSK Biologicals' HPV-16/18 L1 VLP AS04 Vaccine (GSK-580299) in Healthy Female Children 4-6 Years Old

Infections, Papillomavirus

Panama, Mexico, Colombia
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' Human Papillomavirus (HPV) Vaccine (GSK-580299) and Merck's Gardasil Vaccine When Administered According to Alternative 2-dose Schedules in 9-14 Year Old Females

Infections, Papillomavirus

Singapore, Hong Kong, France, Sweden
GlaxoSmithKline

Completed

The Safety Evaluation of the GSK-580299 Vaccine in Women From the Control Group in the Primary NCT00294047 Study

Infections, Papillomavirus

Russian Federation, Singapore, Australia, Portugal
GlaxoSmithKline

Completed

Human Papillomavirus (HPV) Vaccine (Cervarix TM) Efficacy, Immunogenicity & Safety Trial in Adult Japanese Women With GSK Biologicals HPV-16/18 Vaccine

Infections, Papillomavirus

Japan
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of GSK Biologicals' Human Papillomavirus 580299 Vaccine in Healthy Female Subjects

Infections, Papillomavirus

China
GlaxoSmithKline

Completed

Evaluation of the Immune and Safety Response of GlaxoSmithKline (GSK) Biologicals' HPV Vaccine in Healthy Indian Women

Infections, Papillomavirus

India
GlaxoSmithKline

Completed

Safety Evaluation of a Human Papillomavirus (HPV) Vaccine in Healthy Female Control Subjects From the GSK HPV 023 Study

Infections, Papillomavirus

Brazil
GlaxoSmithKline

Completed

Human Papillomavirus Vaccine Safety & Immunogenicity Trial in Healthy Young Adult Women With HPV Vaccine (GSK1674330A)

Infections, Papillomavirus

Belgium
GlaxoSmithKline

Completed

Dose-Comparison Study to Evaluate the Safety and Immunogenicity of MEDI-517 (GSK 580299) in Healthy Adult Females

Infections, Papillomavirus
Leiden University Medical Center

Recruiting

Fine Needle aSpiration of Lymph nodEs to Study vAccine-induced Immunity (SEA)

Vaccine-Preventable Diseases

Netherlands

3

Subscribe